Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.47 |
| ▸ | NAMPT | P43490 | 6/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576226 | 0.91 | RIPK2 (0.48) | RIPK2RPS6KA3NPC1MAPTRPS6KA2 | |
| SCHEMBL14575905 | 0.86 | RIPK2 (0.49) | RIPK2RPS6KA3MAPTRPS6KA2PTGER4 | |
| SCHEMBL14576193 | 0.86 | RIPK2 (0.52) | RIPK2PTGER4 | |
| SCHEMBL12284533 | 0.85 | RIPK2 (0.56) | RIPK2NPC1MAPTPTGER4 | |
| SCHEMBL2551496 | 0.84 | PTGER4 (0.54) | RIPK2PTGER4 | |
| SCHEMBL14576706 | 0.80 | RIPK2 (0.56) | RIPK2PTGER4 | |
| SCHEMBL14576558 | 0.79 | RIPK2 (0.60) | RIPK2PTGER4 | |
| SCHEMBL14575975 | 0.79 | RIPK2 (0.43) | RIPK2MAPTPTGER4 | |
| SCHEMBL14576160 | 0.78 | RIPK2 (0.59) | RIPK2PTGER4 | |
| SCHEMBL14576632 | 0.78 | RIPK2 (0.72) | RIPK2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | claimed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | RIPK2 255/4885RPS6KA3 49/4885NAMPT 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.